Contrasting toxicity data from CD19-directed CAR T cell trials with maturing data from several trials using CAR T cells in multiple myeloma may inform to what degrees toxicity profiles differ with the change of the target antigen—information that may help anticipate toxicity profiles with CAR-modified IECs in AML. The gene discussed is CD19; the disease is AL amyloidosis.